Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma

GSK

24 July 2025 - Two head-to-head Phase 3 trials demonstrated superior efficacy, including overall survival versus a daratumumab-based triplet in DREAMM-7.

GSK today announced the approval of Blenrep in the European Union for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone in patients who have received at least one prior therapy including lenalidomide.

Read GSK press release

Michael Wonder

Posted by:

Michael Wonder